Gross cystic breast disease: Overview and directions for future research

M. J. Reed, A. Angeli, J. H. Thijssen, A. Milewicz, I. Számel, J. Huber, A. Harlozinska-Szmyrka, J. Tóth, J. Kornafel

Research output: Short survey

4 Citations (Scopus)


As previously discussed, there is now a growing consensus that the presence of GCBD indicates an increased risk for breast cancer in later life. It is therefore important for the management of patients to determine whether the cyst is of the higher risk type (Type I). Further biochemical analysis of BCF is desirable to identify markers of cancer risk. By combining such biochemical studies with the long-term follow-up of patients with Type I cysts, valuable new information will be provided to assist in the future management of patients. The incidence of GCBD appears to be on the increase in some Eastern European countries. By carrying out long-term studies in such countries further insight into the aetiology of GCBD may be obtainable. In these countries, it should be possible to relate changes in the incidence of GCBD to changes in dietary habits, and thus provide important information as to the role of diet in the aetiology of this disease. The lack of effective therapy for GCBD indicates that there is an urgent need to carefully evaluate a number of potential therapeutic agents for use in treating this disease. Only by carrying out basic studies to determine the course of the disease, however, will it be possible to develop a rational form of therapy for this disease. The meeting in Wroclaw, Poland, concluded with the consensus that progress in understanding the development of GCBD, its relationship with breast cancer and the development of effective endocrine therapies would be greatly assisted by pursuing large-scale, multi-centre studies. Such collaborative research will enable the collection and characterisation of large numbers of BCF samples. The establishment of a BCF bank would help to rapidly evaluate the potential of any new markers of breast cancer risk which may be identified in BCF. Furthermore, such multi-centre studies should allow a number of new endocrine therapies for this disease to be quickly evaluated, using sufficient numbers of patients to determine the most effective form of therapy for this widespread disease.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalEndocrine-Related Cancer
Issue number2
Publication statusPublished - jan. 1 1994

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gross cystic breast disease: Overview and directions for future research'. Together they form a unique fingerprint.

  • Cite this

    Reed, M. J., Angeli, A., Thijssen, J. H., Milewicz, A., Számel, I., Huber, J., Harlozinska-Szmyrka, A., Tóth, J., & Kornafel, J. (1994). Gross cystic breast disease: Overview and directions for future research. Endocrine-Related Cancer, 1(2), 9-13.